- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06561685
Eine Studie zu LY4050784 bei Teilnehmern mit fortgeschrittenen oder metastasierten soliden Tumoren
Eine offene, multizentrische Studie zu LY4050784, einem selektiven SMARCA2/BRM-Inhibitor, bei fortgeschrittenen soliden Tumortumoren mit SMARCA4/BRG1-Veränderungen
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Berlin, Deutschland, 10117
- Charite-Universitatsmedizin Berlin
-
Essen, Deutschland, 45147
- Universitaetsklinikum Essen
-
Frankfurt am Main, Deutschland, 60488
- Krankenhaus Nordwest
-
-
-
-
-
Bordeaux, Frankreich, 33 076
- Institut Bergonie
-
Paris, Frankreich, 75248
- Institut Curie
-
Villejuif, Frankreich, 94800
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
-
-
-
-
-
Chūōku, Japan, 104-0045
- National Cancer Center Hospital
-
Kashiwa, Japan, 277-8577
- National Cancer Center Hospital East
-
Kōtō City, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
Nagaizumi-cho,Sunto-gun, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spanien, 28040
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
-
-
-
-
-
Ilsandong-gu, Südkorea, 10408
- National Cancer Center
-
Seoul, Südkorea, 03722
- Severance Hospital, Yonsei University Health System
-
Suwon, Südkorea, 16247
- The Catholic University of Korea, St. Vincent's Hospital
-
-
-
-
California
-
Santa Monica, California, Vereinigte Staaten, 90404
- UCLA
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Health Hospital
-
Denver, Colorado, Vereinigte Staaten, 80218
- Sarah Cannon Research Institute at HealthOne
-
-
Florida
-
Lake Mary, Florida, Vereinigte Staaten, 32746
- Florida Cancer Specialists ORLANDO/DDU
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami
-
-
Illinois
-
New Lenox, Illinois, Vereinigte Staaten, 60451
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University Medical Center
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Hospital
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Vereinigte Staaten, 37232-6307
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- SCRI Oncology Partners
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- USO-Virginia Cancer Specialists, PC
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:
- Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
- Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
-
Prior Systemic Therapy Criteria:
- Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
- Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.
- Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
-
Measurability of disease
- Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
- Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
- Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
- Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
- Participants with history of increased risk of prolonged QT or significant arrythmia
- Significant cardiovascular disease
- Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
- Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
- Participants with history of active autoimmune diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: LY4050784 (Phase 1a - Dose Escalation)
Escalating doses of LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Optimization/Part A)
Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part B)
LY4050784 administered orally. |
Oral |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1
LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a
LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
|
Experimental: LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b
LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
Number of participants with dose-limiting toxicities (DLTs) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Bewertung der PK -Eigenschaften von LY4050784 in Kombination Kohorten: Maximale Konzentration (CMAX) PK: CMAX von LY4050784
Zeitfenster: Zyklus 1 (Tag 8)
|
Zyklus 1 (Tag 8)
|
|
|
Bewertung der PK -Eigenschaften von LY4050784 in Kombination Kohorten: Zeit bis maximale Konzentration (TMAX) PK: TMAX von LY4050784
Zeitfenster: Zyklus 1 (Tag 8)
|
Zyklus 1 (Tag 8)
|
|
|
Bewertung der PK -Eigenschaften von LY4050784 in Kombination Kohorten: Bereich unter der Konzentration gegenüber der Zeitkurve (AUC)
Zeitfenster: Zyklus 1 (Tag 8)
|
Zyklus 1 (Tag 8)
|
|
|
To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)
Zeitfenster: Cycle 1 (Day 8)
|
PK: Cmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)
Zeitfenster: Cycle 1 (Day 8)
|
PK: Tmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)
Zeitfenster: Cycle 1 (Day 8)
|
PK: AUC of LY4050784 |
Cycle 1 (Day 8)
|
|
Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)
Zeitfenster: Up to Approximately 48 Months or 4 Years
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Lungenkrankheit
- Neubildungen, Drüsen und Epithelien
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Neoplastische Prozesse
- Karzinom
- Neubildungen, Plattenepithelzellen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Pathologische Zustände, Anzeichen und Symptome
- Lungentumoren
- Karzinom, Plattenepithel
- Neoplasma Metastasierung
- Karzinom, nicht-kleinzellige Lunge
- Adenokarzinom
- Aminosäuren, Peptide und Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Koordinationskomplexe
- Guanine
- Hypoxanthen
- Purinonen
- Purines
- Glutamaten
- Aminosäuren, saur
- Aminosäuren
- Aminosäuren, Dicarboxylic
- Taxoid
- Cyclodececane
- Diterpene
- Gesundheitsökonomie und Organisationen
- Platinverbindungen
- Wirtschaft
- Pemetrexed
- Carboplatin
- Paclitaxel
- Cisplatin
- Pembrolizumab
- Steuern
Andere Studien-ID-Nummern
- 27191
- J5M-OX-JOXA (Andere Kennung: Eli Lilly and Company)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .